James R. Appleman

Bringing over 20 years of experience in the application of information technologies to drug discovery and development, Dr. Appleman joined Annai Systems in October 2015. Prior to joining Annai, he was a co-founder of eFFECTOR Therapeutics, where he established both the bioinformatics infrastructure and technology base to support eFFECTOR’s unique drug discovery and development programs, which target dysregulated mRNA translation. Dr. Appleman previously served as chief scientific officer at Anadys Pharmaceuticals Inc., where he played pivotal roles in the invention, characterization, and clinical development of the company’s drug candidates Setrobuvir and ANA77. He was also instrumental in the acquisition of Anadys by Roche. Prior to joining Anadys, Dr. Appleman held positions at Gensia Inc., and its subsidiary Metabasis Therapeutics, and was a faculty member at St. Jude Children’s Research Hospital. He received a doctorate in biochemistry from Oklahoma State University and completed his postdoctoral training at Dartmouth Medical School.